COVID-19 Summit Sees Progress On Test-And-Treat, IP Licensing, & Funding Commitments
$712m More Pledged For World Bank Pandemic Preparedness Fund
Executive Summary
Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.
You may also be interested in...
Preparing for COVID 2.0: Understanding Animal ‘Spillover’ And Addressing Excessive Nationalism
Former Merck executive Julie Gerberding, Biocon chief Kiran Mazumdar-Shaw, ModeX Therapeutics’ John Mascola, and NIH’s Larry Tabak discuss what it will take to better handle the next pandemic.
NGOs Praise C-TAP COVID-19 Deals But Say Much More Needs To Be Done
With efforts continuing to maximize access to medical countermeasures against the pandemic threat, a webinar organized by NGOs looked at progress with and the shortcomings of the WHO’s C-TAP initiative, recent moves by the WHO on access provisions in funding agreements, and plans for a global C-TAP database.
Coronavirus Notebook: Global COVID-19 Summit To Press For More Funding For Vaccines & Treatments, WHO Calls For End To IP Waiver ‘Stalemate’
CEPI has announced funding for a “variant-proof” vaccine being developed by a multidisciplinary consortium. The European Medicines Agency's new committee on drug shortages in health crises has held its first meeting, and the European Parliament’s new COVID-19 committee will quiz the health commissioner on the EU’s vaccines strategy and response to the pandemic.